Share Price and Basic Stock Data
Last Updated: December 13, 2025, 9:03 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sun Pharma Advanced Research Company Ltd (SPARC) operates in the pharmaceutical sector, focusing on research and development of new drug formulations. The company has faced significant revenue fluctuations over the years, as evidenced by their reported sales figures. For instance, sales peaked at ₹253 Cr in FY 2021 but dropped to ₹137 Cr in FY 2022, before bouncing back to ₹239 Cr in FY 2023. However, recent quarterly sales show a worrying trend, with revenues declining to ₹21 Cr in September 2023 and further to ₹14 Cr by December 2023. This decline indicates potential challenges in sustaining revenue growth, possibly due to market competition or delays in product approvals. The overall trajectory suggests that SPARC is struggling to maintain a consistent revenue stream, which raises concerns for investors about the company’s ability to capitalize on its research efforts.
Profitability and Efficiency Metrics
Profitability remains a critical issue for SPARC, with the company recording a net profit of -₹223 Cr in FY 2023, worsening to -₹388 Cr in FY 2024. The operating profit margin (OPM) has also shown a dismal performance, with figures as low as -740% in December 2023. The company’s expenses have significantly outstripped revenues, climbing to ₹453 Cr in FY 2023. Furthermore, the interest coverage ratio stands at a concerning -35.55x, indicating that SPARC is generating far less operating income than required to cover interest expenses. The cash conversion cycle of 82 days implies inefficiencies in managing receivables, which could further strain cash flows. These profitability metrics paint a stark picture of a company grappling with operational inefficiencies and high expenditures, emphasizing the need for stringent cost controls and strategic pivots to restore profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of SPARC raises several red flags, particularly concerning its reserves and borrowings. As of FY 2025, the company reported reserves of -₹381 Cr, highlighting a negative equity position that could deter potential investors. The total borrowings increased to ₹417 Cr, significantly higher than the reserves, showcasing a reliance on debt financing. The price-to-book value (P/BV) ratio stands at a staggering -22.14x, suggesting that the market perceives the company’s assets as significantly undervalued or that it is facing severe financial distress. Moreover, with a current ratio of 0.07, SPARC appears ill-equipped to meet its short-term liabilities, which raises concerns regarding liquidity. These financial ratios underscore the precariousness of SPARC’s financial health, necessitating urgent measures to restore balance sheet stability.
Shareholding Pattern and Investor Confidence
Investor confidence in SPARC appears to be waning, as reflected in the shareholding pattern. Promoters hold a substantial 65.67% stake, a slight decrease from previous quarters, which may signal a lack of confidence in the company’s future prospects. Foreign institutional investors (FIIs) have also reduced their stake significantly from 3.48% in December 2022 to just 1.76% by September 2025. This trend is concerning, as declining FII interest often correlates with diminished market confidence. Domestic institutional investors (DIIs) have also been cautious, holding a mere 1.05% of the company. The total number of shareholders has fluctuated, indicating some volatility in retail investor sentiment. This shifting landscape suggests that the market is increasingly skeptical about SPARC’s ability to turn around its financial performance, which could impact future funding opportunities and valuations.
Outlook, Risks, and Final Insight
Looking ahead, SPARC faces a multitude of risks that could further complicate its recovery. The ongoing decline in revenues and profitability raises questions about the sustainability of its business model. Additionally, the company’s substantial debt burden poses a risk if it fails to generate sufficient cash flows to meet its obligations. On the flip side, the potential for new drug developments could serve as a catalyst for growth, provided the company can navigate regulatory hurdles effectively. Investors should keep a close eye on the company’s ability to stabilize its financials, improve operational efficiency, and rebuild market confidence. In an environment where operational performance is under scrutiny, SPARC’s management must implement robust strategies for recovery. The path forward is fraught with challenges, but with the right moves, SPARC may still find opportunities for revitalization in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mipco Seamless Rings (Gujarat) Ltd | 9.34 Cr. | 26.0 | 37.4/22.0 | 3.71 | 0.00 % | % | % | 10.0 | |
| MPIL Corporation Ltd | 26.2 Cr. | 460 | 787/362 | 242 | 0.10 % | 12.8 % | 15.5 % | 10.0 | |
| FGP Ltd | 12.9 Cr. | 10.8 | 13.7/7.32 | 3.09 | 0.00 % | 0.00 % | 0.89 % | 10.0 | |
| Logica Infoway Ltd | 401 Cr. | 225 | 272/173 | 29.3 | 53.0 | 0.00 % | 14.3 % | 14.1 % | 10.0 |
| CRP Risk Management Ltd | 10.8 Cr. | 6.18 | 10.6/5.61 | 34.6 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| Industry Average | 8,468.50 Cr | 286.38 | 42.50 | 104.34 | 0.03% | 48.42% | 7.44% | 9.00 |
All Competitor Stocks of Sun Pharma Advanced Research Company Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28 | 32 | 131 | 48 | 24 | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 |
| Expenses | 107 | 94 | 115 | 137 | 126 | 113 | 116 | 124 | 112 | 117 | 89 | 81 | 62 |
| Operating Profit | -78 | -63 | 16 | -90 | -102 | -91 | -103 | -108 | -95 | -104 | -74 | -54 | -52 |
| OPM % | -275% | -198% | 12% | -188% | -427% | -432% | -740% | -649% | -566% | -808% | -499% | -198% | -543% |
| Other Income | 0 | 0 | 0 | 11 | 10 | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 |
| Interest | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | -82 | -68 | 10 | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -82 | -68 | 10 | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 |
| EPS in Rs | -3.03 | -2.52 | 0.37 | -2.53 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 | -1.88 | -1.60 |
Last Updated: August 20, 2025, 3:00 am
Below is a detailed analysis of the quarterly data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 17.00 Cr..
- For Expenses, as of Jun 2025, the value is 62.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 81.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 19.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -52.00 Cr.. The value appears strong and on an upward trend. It has increased from -54.00 Cr. (Mar 2025) to -52.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is -543.00%. The value appears to be declining and may need further review. It has decreased from -198.00% (Mar 2025) to -543.00%, marking a decrease of 345.00%.
- For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -52.00 Cr.. The value appears strong and on an upward trend. It has increased from -61.00 Cr. (Mar 2025) to -52.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -52.00 Cr.. The value appears strong and on an upward trend. It has increased from -61.00 Cr. (Mar 2025) to -52.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.60. The value appears strong and on an upward trend. It has increased from -1.88 (Mar 2025) to -1.60, marking an increase of 0.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:35 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 167 | 156 | 161 | 181 | 78 | 183 | 77 | 253 | 137 | 239 | 76 | 72 | 60 |
| Expenses | 134 | 191 | 224 | 304 | 321 | 334 | 387 | 388 | 324 | 453 | 479 | 399 | 306 |
| Operating Profit | 34 | -35 | -63 | -123 | -243 | -151 | -310 | -135 | -187 | -214 | -404 | -327 | -247 |
| OPM % | 20% | -23% | -39% | -68% | -310% | -83% | -404% | -53% | -136% | -90% | -534% | -456% | -414% |
| Other Income | 10 | 3 | 3 | 14 | 54 | 14 | 10 | 5 | 7 | 11 | 29 | 2 | 9 |
| Interest | 6 | 0 | 2 | 2 | 0 | 0 | 3 | 11 | 13 | 8 | 2 | 9 | 21 |
| Depreciation | 4 | 7 | 8 | 8 | 8 | 8 | 9 | 11 | 10 | 12 | 12 | 11 | 10 |
| Profit before tax | 34 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -345 | -269 |
| Tax % | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | 30 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -345 | -269 |
| EPS in Rs | 1.23 | -1.60 | -2.83 | -4.82 | -7.85 | -5.55 | -11.92 | -5.77 | -7.48 | -6.86 | -11.96 | -10.64 | -8.28 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -233.33% | -75.00% | -70.00% | -65.55% | 26.40% | -115.17% | 51.60% | -34.44% | -9.85% | -73.99% | 11.08% |
| Change in YoY Net Profit Growth (%) | 0.00% | 158.33% | 5.00% | 4.45% | 91.94% | -141.57% | 166.77% | -86.04% | 24.58% | -64.14% | 85.07% |
Sun Pharma Advanced Research Company Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | -1% |
| 3 Years: | -19% |
| TTM: | -6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -30% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | -4% |
| 3 Years: | -14% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 1:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:02 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 25 | 25 | 26 | 26 | 26 | 27 | 32 | 32 | 32 | 32 |
| Reserves | 116 | 76 | 8 | 133 | 160 | 270 | -45 | -194 | 4 | 480 | 92 | -253 | -381 |
| Borrowings | 5 | 4 | 56 | 3 | 2 | 2 | 67 | 236 | 79 | 16 | 56 | 265 | 417 |
| Other Liabilities | 39 | 39 | 75 | 111 | 122 | 101 | 224 | 162 | 170 | 302 | 305 | 284 | 252 |
| Total Liabilities | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 | 329 | 320 |
| Fixed Assets | 64 | 67 | 70 | 69 | 52 | 58 | 104 | 91 | 92 | 106 | 103 | 95 | 162 |
| CWIP | 1 | 0 | 1 | 1 | 3 | 24 | 32 | 5 | 26 | 27 | 44 | 54 | 1 |
| Investments | 6 | 0 | 0 | 10 | 108 | 211 | 8 | 6 | 12 | 291 | 2 | 0 | 0 |
| Other Assets | 112 | 76 | 92 | 192 | 146 | 106 | 128 | 127 | 150 | 406 | 338 | 179 | 156 |
| Total Assets | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 | 329 | 320 |
Below is a detailed analysis of the balance sheet data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 32.00 Cr..
- For Reserves, as of Sep 2025, the value is -381.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -253.00 Cr. (Mar 2025) to -381.00 Cr., marking a decline of 128.00 Cr..
- For Borrowings, as of Sep 2025, the value is 417.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 265.00 Cr. (Mar 2025) to 417.00 Cr., marking an increase of 152.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 252.00 Cr.. The value appears to be improving (decreasing). It has decreased from 284.00 Cr. (Mar 2025) to 252.00 Cr., marking a decrease of 32.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 320.00 Cr.. The value appears to be improving (decreasing). It has decreased from 329.00 Cr. (Mar 2025) to 320.00 Cr., marking a decrease of 9.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 162.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Mar 2025) to 162.00 Cr., marking an increase of 67.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 54.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 53.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 156.00 Cr.. The value appears to be declining and may need further review. It has decreased from 179.00 Cr. (Mar 2025) to 156.00 Cr., marking a decrease of 23.00 Cr..
- For Total Assets, as of Sep 2025, the value is 320.00 Cr.. The value appears to be declining and may need further review. It has decreased from 329.00 Cr. (Mar 2025) to 320.00 Cr., marking a decrease of 9.00 Cr..
However, the Borrowings (417.00 Cr.) are higher than the Reserves (-381.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 29.00 | -39.00 | -119.00 | -126.00 | -245.00 | -153.00 | -377.00 | -371.00 | -266.00 | -230.00 | -460.00 | -592.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 | 82 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 | 82 |
| Working Capital Days | 127 | 20 | -161 | -60 | -232 | -98 | -842 | -268 | -301 | -193 | -746 | -1,778 |
| ROCE % | 21% | -32% | -71% | -94% | -143% | -62% | -183% | -242% | -218% | -67% | -109% | -298% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 2,995,540 | 0.62 | 40.29 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -10.55 | -11.93 | -7.82 |
| Diluted EPS (Rs.) | -10.55 | -11.93 | -7.82 |
| Cash EPS (Rs.) | -10.17 | -11.55 | -6.50 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -6.68 | 3.88 | 15.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -6.68 | 3.88 | 15.80 |
| Revenue From Operations / Share (Rs.) | 2.21 | 2.33 | 7.36 |
| PBDIT / Share (Rs.) | -9.90 | -11.48 | -6.26 |
| PBIT / Share (Rs.) | -10.28 | -11.87 | -6.62 |
| PBT / Share (Rs.) | -10.56 | -11.92 | -6.86 |
| Net Profit / Share (Rs.) | -10.55 | -11.93 | -6.86 |
| NP After MI And SOA / Share (Rs.) | -10.55 | -11.93 | -6.86 |
| PBDIT Margin (%) | -447.77 | -493.24 | -85.09 |
| PBIT Margin (%) | -465.04 | -509.80 | -90.01 |
| PBT Margin (%) | -477.63 | -512.05 | -93.21 |
| Net Profit Margin (%) | -477.25 | -512.55 | -93.21 |
| NP After MI And SOA Margin (%) | -477.25 | -512.55 | -93.21 |
| Return on Networth / Equity (%) | 0.00 | -307.91 | -43.40 |
| Return on Capital Employeed (%) | 862.23 | -154.06 | -33.00 |
| Return On Assets (%) | -102.07 | -75.18 | -26.81 |
| Long Term Debt / Equity (X) | -0.46 | 0.00 | 0.00 |
| Total Debt / Equity (X) | -1.19 | 0.37 | 0.00 |
| Asset Turnover Ratio (%) | 0.16 | 0.11 | 0.00 |
| Current Ratio (X) | 0.07 | 1.02 | 2.54 |
| Quick Ratio (X) | 0.07 | 1.02 | 2.54 |
| Interest Coverage Ratio (X) | -35.55 | -219.89 | -26.61 |
| Interest Coverage Ratio (Post Tax) (X) | -36.89 | -227.50 | -28.15 |
| Enterprise Value (Cr.) | 5059.27 | 11897.66 | 5712.17 |
| EV / Net Operating Revenue (X) | 70.50 | 157.49 | 23.92 |
| EV / EBITDA (X) | -15.74 | -31.93 | -28.11 |
| MarketCap / Net Operating Revenue (X) | 66.93 | 158.92 | 24.39 |
| Price / BV (X) | -22.14 | 95.47 | 11.36 |
| Price / Net Operating Revenue (X) | 66.93 | 158.93 | 24.39 |
| EarningsYield | -0.07 | -0.03 | -0.03 |
After reviewing the key financial ratios for Sun Pharma Advanced Research Company Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 5. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 5. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For Cash EPS (Rs.), as of Mar 25, the value is -10.17. This value is below the healthy minimum of 3. It has increased from -11.55 (Mar 24) to -10.17, marking an increase of 1.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -6.68. It has decreased from 3.88 (Mar 24) to -6.68, marking a decrease of 10.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -6.68. It has decreased from 3.88 (Mar 24) to -6.68, marking a decrease of 10.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2.21. It has decreased from 2.33 (Mar 24) to 2.21, marking a decrease of 0.12.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -9.90. This value is below the healthy minimum of 2. It has increased from -11.48 (Mar 24) to -9.90, marking an increase of 1.58.
- For PBIT / Share (Rs.), as of Mar 25, the value is -10.28. This value is below the healthy minimum of 0. It has increased from -11.87 (Mar 24) to -10.28, marking an increase of 1.59.
- For PBT / Share (Rs.), as of Mar 25, the value is -10.56. This value is below the healthy minimum of 0. It has increased from -11.92 (Mar 24) to -10.56, marking an increase of 1.36.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 2. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 2. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For PBDIT Margin (%), as of Mar 25, the value is -447.77. This value is below the healthy minimum of 10. It has increased from -493.24 (Mar 24) to -447.77, marking an increase of 45.47.
- For PBIT Margin (%), as of Mar 25, the value is -465.04. This value is below the healthy minimum of 10. It has increased from -509.80 (Mar 24) to -465.04, marking an increase of 44.76.
- For PBT Margin (%), as of Mar 25, the value is -477.63. This value is below the healthy minimum of 10. It has increased from -512.05 (Mar 24) to -477.63, marking an increase of 34.42.
- For Net Profit Margin (%), as of Mar 25, the value is -477.25. This value is below the healthy minimum of 5. It has increased from -512.55 (Mar 24) to -477.25, marking an increase of 35.30.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -477.25. This value is below the healthy minimum of 8. It has increased from -512.55 (Mar 24) to -477.25, marking an increase of 35.30.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -307.91 (Mar 24) to 0.00, marking an increase of 307.91.
- For Return on Capital Employeed (%), as of Mar 25, the value is 862.23. This value is within the healthy range. It has increased from -154.06 (Mar 24) to 862.23, marking an increase of 1,016.29.
- For Return On Assets (%), as of Mar 25, the value is -102.07. This value is below the healthy minimum of 5. It has decreased from -75.18 (Mar 24) to -102.07, marking a decrease of 26.89.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.46. This value is below the healthy minimum of 0.2. It has decreased from 0.00 (Mar 24) to -0.46, marking a decrease of 0.46.
- For Total Debt / Equity (X), as of Mar 25, the value is -1.19. This value is within the healthy range. It has decreased from 0.37 (Mar 24) to -1.19, marking a decrease of 1.56.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.16. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.07, marking a decrease of 0.95.
- For Quick Ratio (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.07, marking a decrease of 0.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -35.55. This value is below the healthy minimum of 3. It has increased from -219.89 (Mar 24) to -35.55, marking an increase of 184.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -36.89. This value is below the healthy minimum of 3. It has increased from -227.50 (Mar 24) to -36.89, marking an increase of 190.61.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,059.27. It has decreased from 11,897.66 (Mar 24) to 5,059.27, marking a decrease of 6,838.39.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 70.50. This value exceeds the healthy maximum of 3. It has decreased from 157.49 (Mar 24) to 70.50, marking a decrease of 86.99.
- For EV / EBITDA (X), as of Mar 25, the value is -15.74. This value is below the healthy minimum of 5. It has increased from -31.93 (Mar 24) to -15.74, marking an increase of 16.19.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 66.93. This value exceeds the healthy maximum of 3. It has decreased from 158.92 (Mar 24) to 66.93, marking a decrease of 91.99.
- For Price / BV (X), as of Mar 25, the value is -22.14. This value is below the healthy minimum of 1. It has decreased from 95.47 (Mar 24) to -22.14, marking a decrease of 117.61.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 66.93. This value exceeds the healthy maximum of 3. It has decreased from 158.93 (Mar 24) to 66.93, marking a decrease of 92.00.
- For EarningsYield, as of Mar 25, the value is -0.07. This value is below the healthy minimum of 5. It has decreased from -0.03 (Mar 24) to -0.07, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sun Pharma Advanced Research Company Ltd:
- Net Profit Margin: -477.25%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 862.23% (Industry Average ROCE: 48.42%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 7.44%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -36.89
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.07
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 42.5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -1.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -477.25%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Plot No. 5 & 6/1, Savli G.I.D.C. Estate, Savli - Vadodara Highway, Vadodra District Gujarat 391775 | secretarial@sparcmail.com http://www.sparc.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dilip S Shanghvi | Chairman & Non-Exe.Director |
| Dr. T Rajamannar | Non Executive Director |
| Ms. Vidhi Shanghvi | Non Executive Director |
| Mr. Venkateswarlu Jasti | Independent Director |
| Ms. Bhavna Doshi | Independent Director |
| Dr. Ferzaan Engineer | Independent Director |
| Dr. Robert J Spiegel | Independent Director |
| Mrs. Rekha Warriar | Independent Director |
FAQ
What is the intrinsic value of Sun Pharma Advanced Research Company Ltd?
Sun Pharma Advanced Research Company Ltd's intrinsic value (as of 15 December 2025) is 19.83 which is 85.53% lower the current market price of 137.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,441 Cr. market cap, FY2025-2026 high/low of 241/109, reserves of ₹-381 Cr, and liabilities of 320 Cr.
What is the Market Cap of Sun Pharma Advanced Research Company Ltd?
The Market Cap of Sun Pharma Advanced Research Company Ltd is 4,441 Cr..
What is the current Stock Price of Sun Pharma Advanced Research Company Ltd as on 15 December 2025?
The current stock price of Sun Pharma Advanced Research Company Ltd as on 15 December 2025 is 137.
What is the High / Low of Sun Pharma Advanced Research Company Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sun Pharma Advanced Research Company Ltd stocks is 241/109.
What is the Stock P/E of Sun Pharma Advanced Research Company Ltd?
The Stock P/E of Sun Pharma Advanced Research Company Ltd is .
What is the Book Value of Sun Pharma Advanced Research Company Ltd?
The Book Value of Sun Pharma Advanced Research Company Ltd is 10.8.
What is the Dividend Yield of Sun Pharma Advanced Research Company Ltd?
The Dividend Yield of Sun Pharma Advanced Research Company Ltd is 0.00 %.
What is the ROCE of Sun Pharma Advanced Research Company Ltd?
The ROCE of Sun Pharma Advanced Research Company Ltd is 298 %.
What is the ROE of Sun Pharma Advanced Research Company Ltd?
The ROE of Sun Pharma Advanced Research Company Ltd is %.
What is the Face Value of Sun Pharma Advanced Research Company Ltd?
The Face Value of Sun Pharma Advanced Research Company Ltd is 1.00.